Neurocrine Biosciences
NBIX
#1371
Rank
A$23.36 B
Marketcap
A$234.31
Share price
0.84%
Change (1 day)
16.14%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2025 : A$0.64 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is A$0.64 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$0.73 B16.36%
2023-12-31A$0.62 B62.76%
2022-12-31A$0.38 B-36.4%
2021-12-31A$0.60 B13.29%
2020-12-31A$0.53 B-24.24%
2019-12-31A$0.70 B28.33%
2018-12-31A$0.55 B16.48%
2017-12-31A$0.47 B
2009-12-31A$12.83 M-41.19%
2008-12-31A$21.82 M1183.98%
2007-12-31A$1.69 M-97.5%
2006-12-31A$68.04 M-16.18%
2005-12-31A$81.18 M-4.99%
2004-12-31A$85.45 M74.33%
2003-12-31A$49.01 M248.02%
2002-12-31A$14.08 M26.39%
2001-12-31A$11.14 M60.99%
2000-12-31A$6.92 M46.72%
1999-12-31A$4.71 M-3.71%
1998-12-31A$4.89 M99.5%
1997-12-31A$2.45 M21.93%
1996-12-31A$2.01 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
A$1.03 B 60.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$13.47 B 1,988.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
A$0.39 M-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$64.04 B 9,822.18%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$103.57 B 15,946.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$91.67 B 14,103.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$0.93 B 44.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A$27.98 M-95.66%๐Ÿ‡บ๐Ÿ‡ธ USA